Vandetanib’s inhibition of viral egress could theoretically be related to its known ability to inhibit receptor tyrosine kinases such as epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR), which is why it is FDA approved to treat certain cancers. The gene discussed is NTRK1; the disease is cancer.